Brief: Hansoh Pharmaceutical Says Risvutatug Rezetecan Included In NMPA Priority Review
22/09/2026 11:22
BRIEF-Hansoh Pharmaceutical Says Risvutatug Rezetecan Included In NMPA Priority Review Sept 22 (Reuters) - Hansoh Pharmaceutical Group Company Limited 3692.HK:
RISVUTATUG REZETECAN FOR INJECTION INCLUDED IN NMPA PRIORITY REVIEW FOR OSTEOSARCOMA
Further company coverage: 3692.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion